RETINALGENIX TECHNOLOGIES INC.

RTGN ·Healthcare, Medical Devices, United States
Financial Statements Cash Flow Statement
Annual Quarterly

Cash Flow Statement

Line Item FY2025 FY2024 FY2023 FY2022 FY2021 FY2020
Operating Activities
Net Income $-2.4M $-4.3M $-2.1M $-3.9M $-2.2M $-2.1M
Depreciation & Amortization
Depreciation $56 $100 $100 $51
Amortization
Stock-Based Compensation $1.0M $2.6M $664.2K $259.3K $307.9K $220.2K
Net Cash from Operating Activities $-558.4K $-741.9K $-451.7K $-199.3K $-1.2M $-1.4M
Investing Activities
Capital Expenditures
Business Acquisitions
Net Cash from Investing Activities
Financing Activities
Dividends Paid
Stock Repurchases
Net Cash from Financing Activities $567.1K $748.0K $451.6K $194.7K $1.2M $1.4M
Net Change in Cash $8.7K $6.1K $-38 $-4.9K $2.7K $-52.2K
Free Cash Flow